

Periprocedural Management (DOAC)

Bleed Risk Evaluation		Whether or not to interrupt
Patient bleeding risk factors? Any one of these: <ul style="list-style-type: none"> major bleeding or ICH < 3 months ago platelet abnormality (including ASA use) prior bleed during previous bridging or similar procedure 	Procedure bleed risk (see below for examples)	
No	Minimal, No clinically important risk	-Do Not interrupt DOAC (time procedure at DOAC trough level)
	Low	-Interrupt DOAC -Do <u>not</u> bridge
	Intermediate, high, uncertain	
Yes	Any bleed risk category	

Examples of Procedure Bleed Risk*

Min. bleed risk		Low bleed risk	High bleed risk		
<ul style="list-style-type: none"> Minor dental procedures Cataract/glaucoma Superficial skin incisions/excisions 	<ul style="list-style-type: none"> Diagnostic GI endoscopy w/ wo biopsy Central catheter removal 	<ul style="list-style-type: none"> GI procedures (eg. colonoscopy, gastroscopy) Cardiac procedures (eg. pacemaker/defib implantation, arterioventricular node ablation, angiography-radial approach) 	<ul style="list-style-type: none"> Surgery requiring neuraxial anesthesia Major intracranial or neuraxial surgery (eg. laminectomy) Major thoracic surgery (eg. lobectomy) 	<ul style="list-style-type: none"> Major cardiac surgery (eg. CABG) Major vascular surgery (eg. carotid endarterectomy) Major orthopedic surgery (eg. arthroplasty) 	<ul style="list-style-type: none"> Major abdominopelvic surgery (eg. bowel resection) Other major cancer or reconstructive surgery

* For full list of procedures, see online appendix to the 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management

DOAC Interruption and Restart¹

DOAC	Procedure Bleed Risk (see next page for examples)	Peri-Procedural DOAC use										
		Day -5	Day -4	Day -3	Day -2	Day -1	Day of proc.	Day +1	Day +2	Day +3	Day +4	
Dabigatran (CrCl ≥ 50 mL/min [†])	High								Resume day 2 or 3 (1 st dose ≥ 48 hrs post-procedure)			
	Low							1 st dose ≥ 24 hrs post-procedure				
Dabigatran (CrCl < 50 mL/min [†])	High								Resume day 2 or 3 (1 st dose ≥ 48 hrs post-procedure)			
	Low							1 st dose ≥ 24 hrs post-procedure				
Rivaroxaban, apixaban, edoxaban [‡]	High								Resume day 2 or 3 (1 st dose ≥ 48 hrs post-procedure)			
	Low							1 st dose ≥ 24 hrs post-procedure				

¹Adapted from: Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant (PAUSE Trial). JAMA Intern Med. Published online August 5, 2019. doi:10.1001/jamainternmed.2019.2431

*The PAUSE trial only included atrial fibrillation patients; however, it may be reasonable to extrapolate results to patients with other indications at similar thromboembolic risk. In addition, few patients had interventional pain procedures, so at this time, either the PAUSE protocol or the ASRA guidelines can be used in these patients.

[†]CrCl calculated using Cockcroft-Gault and actual body weight.

[‡]Edoxaban was not included in the PAUSE Trial protocol but has a similar half-life as rivaroxaban and apixaban.

Disclaimer: This document is for informational purposes only and does not, itself, constitute medical advice. This document is not a replacement for careful medical judgments by qualified medical personnel. There may be information in this document that does not apply to or may be inappropriate for the medical situation at hand.

Copyright 2018, MAQI². For questions or permissions, please email info@magi2.org. Version 1.2, 1/18/21. For additional resources, visit www.anticoagulationtoolkit.org